Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 31/12 - Antivirals
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment of IgA nephropathy.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.

IPC Classes  ?

• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/10 - Spiro-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

Provided herein are methods of treating focal segmental glomerulosclerosis (FSGS), comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and/or fibrosis, reducing the rate of decline in eGFR, delaying the onset of ESKD, decreasing proteinuria, and decreasing fatigue in a subject having FSGS, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 31/12 - Antivirals
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

Provided herein are methods of reducing the incident of disease flares in a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 31/12 - Antivirals
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.

IPC Classes  ?

• A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/33 - Heterocyclic compounds
• A61K 31/00 - Medicinal preparations containing organic active ingredients

Abstract

Provided herein are methods of reducing the incident of disease flares in a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are methods of improving kidney function in a subject in need thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61P 31/12 - Antivirals
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets

Goods & Services

Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biologic preparations for prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; medicines; drugs; therapeutic pharmaceuticals; pharmaceutical preparations; therapeutic agents; biologics; biologic preparations. Scientific research and development services; product research and development; pharmaceutical research and development; conducting clinical trials; providing a website in relation to information in the field of medical and scientific research, product development, product testing in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; provision of scientific research information; providing a website in relation to information in the field of medical and scientific research, product development, product testing; providing a website in relation to information in the field of clinical research; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical and scientific research information in the field of pharmaceuticals. Providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions; providing a web site in relation to medical information; providing medical information; providing health information; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; provision of information in the field of prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing a website in relation to information about investigational medical diagnostics and drugs.

Goods & Services

(1) Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biologic preparations for prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biological tissue cultures for medical purposes. (1) Scientific research and development services for the identification of medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; product research and development in the field of pharmaceuticals; pharmaceutical research and development; conducting clinical trials; providing scientific research information in the field of prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing information in the field of medical and scientific research, product development, product testing in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing information in the field of medical and scientific research, product development, product testing in the field of pharmaceuticals; hosting a website providing information about investigational medical diagnostics and drugs in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing educational information in the field of clinical research in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical and scientific research information in the field of pharmaceuticals; hosting a web site featuring medical information in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions. (2) Providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions; providing medical information in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing health information to patients in the field of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals.

Abstract

Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and/or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.

IPC Classes  ?

• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus

Abstract

The present invention relates to methods and compositions for the treatment of diseases with STING agonists. As described hereinafter, STING activation can be modulated to induce local versus systemic immune activation. At lower doses, intratumoral dosing of STING agonists can produce a robust tumor-specific T-cell response capable of ablating a target tumor at a site distal to the STING agonist administration. At higher doses, the distal anti-tumor response is reduced, and ablation of tumor-draining lymph nodes is observed. It is possible to inhibit this ablation of the tumor-draining lymph nodes by co-administration of a TNF antagonist. This co-administration of STING agonists and TNF antagonists can permit the administration of either increased concentrations of STING agonist or STING agonists having greater activity, while maintaining effective tumor control and generation of an anti-tumor adaptive immune response.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 35/00 - Antineoplastic agents

Goods & Services

(1) Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biologic preparations for prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biological tissue cultures for medical purposes. (1) Scientific research and development services for the identification of medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; product research and development in the field of pharmaceuticals; pharmaceutical research and development; conducting clinical trials; providing scientific research information in the field of prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing information in the field of medical and scientific research, product development, product testing in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing information in the field of medical and scientific research, product development, product testing in the field of pharmaceuticals; hosting a website providing information about investigational medical diagnostics and drugs in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; hosting a website providing educational information in the field of clinical research in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical and scientific research information in the field of pharmaceuticals; hosting a web site featuring medical information in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions. (2) Providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions; providing medical information in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing health information to patients in the field of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals.

Goods & Services

Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, therapeutic agents for use in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; biologic preparations for prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; medicines; drugs; therapeutic pharmaceuticals; pharmaceutical preparations; therapeutic agents; biologics; biologic preparations. Scientific research and development services; product research and development; pharmaceutical research and development; conducting clinical trials; providing a website in relation to information in the field of medical and scientific research, product development, product testing in relation to prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; provision of scientific research information; providing a website in relation to information in the field of medical and scientific research, product development, product testing; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical and scientific research information in the field of pharmaceuticals. Providing information relating to the diagnostic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions; providing a web site in relation to medical information; providing medical information; providing health information; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; provision of information in the field of prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions; providing a website in relation to information about investigational medical diagnostics and drugs.

Goods & Services

Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, biologics, biologic preparations and therapeutic agents, all for use by prescription in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions, and not distributed in first aid kits

Goods & Services

Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, biologics, biologic preparations and therapeutic agents, all for use by prescription in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions, and not distributed in first aid kits

Goods & Services

Medicines, drugs, therapeutic pharmaceuticals, pharmaceutical preparations, biologics, biologic preparations and therapeutic agents, all for use by prescription in the prevention and treatment of kidney, renal, nephrological, glomerular, and urological diseases, disorders and conditions, and not distributed in first aid kits

Abstract

The present invention provides the cyclic dinucleotide compound 2′2′-RR-(3′F-A)(3′F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.

IPC Classes  ?

• A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs.

IPC Classes  ?

• A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 35/00 - Antineoplastic agents
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07H 19/213 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Abstract

The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.

IPC Classes  ?

• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 17/06 - Antipsoriatics
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 517/00 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′- or 3′-mono-fluoro substituted, or 2′3′-di-fluoro substituted mixed linkage 2′,5′-3′,5′ CDNs.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 39/12 - Viral antigens
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07H 19/213 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
• A61K 39/385 - Haptens or antigens, bound to carriers

Abstract

It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.

IPC Classes  ?

• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07H 19/213 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 39/12 - Viral antigens
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

IPC Classes  ?

• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and/or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation